Hospitals Cry Foul After Eli Lilly Withholds 340B Discounts
Katie Adams / medcitynews - Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that the company has no legal authority to create its own compliance requirements…
AI Summary: Eli Lilly has begun denying 340B program discounts to participating hospitals after issuing an ultimatum, prompting sharp criticism from safety-net providers. Hospitals say the move will squeeze margins and threaten patient access to affordable medicines. The dispute centers on manufacturer discount eligibility and contract terms as providers scramble to quantify the financial hit.
- Federal 340B reforms and CMS payment proposals (3)
- Hospitals protest Lilly denying 340B discounts (4)
- Legal rulings and stakeholder reactions to 340B fight (3)
Federal 340B reforms and CMS payment proposals
Hospitals protest Lilly denying 340B discounts
Legal rulings and stakeholder reactions to 340B fight
Congressional Budget Office calls for more research on No Surprises Act unintended impacts
fiercehealthcare - The nonpartisan office is seeking more information on the law’s impact on healthcare prices, network participation, ownership structures and more.
AI Summary: The Congressional Budget Office has called for additional research into the No Surprises Act, urging deeper study of the law’s unintended consequences on pricing, provider networks and patient costs. Federal agencies and stakeholders are being pressed to produce better evidence so policymakers can evaluate whether the law’s goals align with real-world effects.